Oxfam is closely watching the outcome of Novartis’ endless and highly
damaging challenge to Section 3(d) of India’s Patent Act. We are profoundly disappointed that Novartis has continued to pursue legal action against the Indian Government. Five years ago, hundreds of thousands of people called upon Novartis to drop its legal challenge against the Indian. Today, over 2 billion people still lack regular access to affordable medicines, and yet Novartis has persisted. Oxfam is seriously concerned that if Novartis succeeds, it will lead to long term and profound changes in India’s patent system that will undermine generic competition and access to affordable,low-cost medicines.
- A ‘New’ Recipe for Trade
- Indian pharma at odds with US trade group over USTR Priority Watch List
- Healthcare Groups Challenge Patents On Three New Hep-C Drugs In India
- Healthcare and patient groups oppose patents on crucial hepatitis C drugs
- Flawed patents on hepatitis C drugs latest to be challenged in global push for access